Lipid accumulation product or lap as an up-to-date clinical biochemical marker of human obesity

View or download the full article: 
PDF icon health-risk-analysis-2019-2-18.pdf
UDC: 
616-056.52
DOI: 
10.21668/health.risk/2019.2.18.eng
Authors: 

A.M. Kaneva, E.R. Bojko

Organization: 

Institute of Physiology, Komi Science Centre, the Ural Branch of the Russian Academy of Sciences, 50 Pervomaiskaya Str., Syktyvkar, 167982, Russian Federation

Abstract: 

Obesity is a grave medical and social problem causing significant hazards for human health due to frequent occurrence of grave concomitant diseases. Visceral obesity is considered to be the most hazardous. Contemporary diagnostics which allows to reveal visceral obesity both during screening examinations of people who are considered to be conditionally healthy and in patients who suffer from cardiovascular diseases is becoming a very promising trend both in primary and secondary prevention.

The review focuses on an up-to-date marker used to detect visceral obesity, namely, lipid accumulation product or LAP. This index was first introduced by Kahn H.S. in 2005 and is calculated on the basis of two variables, waist circumference (cm) and fasting concentration of triglycerides (mmol/l). When a biochemical and an anthropometric parameter are applied simultaneously to calculate LAP, it allows not only to assess how fats are distributed in a body but also to reflect functional state of fat tissues.

LAP index is widely used as a marker showing there are metabolic disorders in a body (metabolic syndrome, diabetes, resistance to insulin, or nonalcoholic fatty liver disease) and as a cardiovascular diseases predictor. Besides, LAP index, when used to identify obesity phenotype, allows to assign people with overweight into a "metabolically healthy" category or "metabolically ill" one and to reveal patients suffering from metabolic obesity among people with normal body weight. A lot of research revealed that LAP index had a very good diagnostic and predictive potential as regards metabolic and cardiovascular diseases and was a more precise marker of cardio-metabolic risks than conventional anthropometric parameters. The review highlights LAP value ranges, its sex and age peculiarities, as well as a character and an extent to which LAP values change in case of certain diseases. It also dwells on advantages and drawbacks of LAP practical application.

Keywords: 
lipid accumulation product (LAP), waist circumference, triglycerides, body mass index, obesity, metabolic syndrome, cardiovascular diseases
Kaneva A.M., Bojko E.R. Lipid accumulation product or lap as an up-to-date clinical biochemical marker of human obesity. Health Risk Analysis, 2019, no. 2, pp. 164–174. DOI: 10.21668/health.risk/2019.2.18.eng
References: 
  1. Kahn H.S. Estimating adult metabolic risk from a lipid accumulation product. Am. J. Epidemiol., 2004, vol. 159, no. 11, pp. 14.
  2. Kahn H.S. The lipid accumulation product is better than body mass index for identifying diabetes. Am. J. Epidemiol., 2005, vol. 161, no. 11, pp. 51.
  3. Kahn H.S. The «lipid accumulation product» performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord, 2005, vol. 5, pp. 26. DOI: 10.1186/1471-2261-5-26
  4. Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Almeras N. [et al.]. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation, 2000, vol. 102, no. 2, pp. 179–184.
  5. Kahn H.S., Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerols. Am. J. Clin. Nutr., 2003, vol. 78, no. 5, pp. 928–934. DOI: 10.1093/ajcn/78.5.928
  6. Shah N.R., Braverman E.R. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PLoS One, 2012, vol. 7, no. 4, pp. e33308. DOI: 10.1371/journal.pone.0033308
  7. Ibrahim M.M. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev, 2010, vol. 11, no. 1, pp. 11–18. DOI: 10.1111/j.1467-789X.2009.00623.x
  8. Ebbert J.O., Jensen M.D. Fat depots, free fatty acids, and dyslipidemia. Nutrients, 2013, vol. 5, no. 2, pp. 498–508. DOI: 10.3390/nu5020498
  9. Després J.P., Lemieux I., Bergeron J., Pibarot P., Mathieu P., Larose E. [et al.]. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb. Vasc. Biol., 2008, vol. 28, no. 6, pp. 1039–1049. DOI: 10.1161/ATVBAHA.107.159228
  10. Wang H., Liu A., Zhao T., Gong X., Pang T., Zhou Y. [et al.]. Comparison of anthropometric indices for predicting the risk of metabolic syndrome and its components in Chinese adults: a prospective, longitudinal study. BMJ Open, 2017, vol. 7, no. 9, pp. e016062. DOI: 10.1136/bmjopen-2017-016062
  11. Ray L., Ravichandran K., Nanda S.K. Comparison of lipid accumulation product index with body mass index and waist circumference as a predictor of metabolic syndrome in Indian population. Metab. Syndr. Relat .Disord., 2018, vol. 16, no. 5, pp. 240–245. DOI: 10.1089/met.2017.0119
  12. Li R., Li Q., Cui M., Yin Z., Li L., Zhong T. [et al.]. Clinical surrogate markers for predicting metabolic syndrome in middle-aged and elderly Chinese. J. Diabetes Investig, 2018, vol. 9, no. 2, pp. 411–418. DOI: 10.1111/jdi.12708
  13. Xia C., Li R., Zhang S., Gong L., Ren W., Wang Z., Li Q. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur. J. Clin. Nutr., 2012, vol. 66, no. 9, pp. 1035–1038. DOI: 10.1038/ejcn.2012.83
  14. Mazidi M., Kengne A.P., Katsiki N., Mikhailidis D.P., Banach M. Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. J. Diabetes Complications, 2018, vol. 32, no. 3, pp. 266–270. DOI: 10.1016/j.jdiacomp.2017.10.007
  15. Wakabayashi I., Daimon T. A strong association between lipid accumulation product and diabetes mellitus in Japanese women and men. J. Atheroscler. Thromb., 2014, vol. 21, no. 3, pp. 282–288. DOI: 10.5551/jat.20628
  16. Bedogni G., Kahn H.S., Bellentani S., Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol, 2010, vol. 10, pp. 98. DOI: 10.1186/1471-230X-10-98
  17. Dai H., Wang W., Chen R., Chen Z., Lu Y., Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond), 2017, vol. 14, pp. 49. DOI: 10.1186/s12986-017-0206-2
  18. Chan L., Xue H., Xiaoya Z., Jiajia X., Wei R., Linman L. [et al.]. Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in patients with adult growth hormone deficiency. Exp. Clin. Endocrinol. Diabetes, 2016, vol. 124, no. 4, pp. 220–224. DOI: 10.1055/s-0035-1569402
  19. Rotter I., Rył A., Szylińska A., Pawlukowska W., Lubkowska A., Laszczyńska M. Lipid accumulation product (LAP) as an index of metabolic and hormonal disorders in aging men. Exp. Clin. Endocrinol. Diabetes, 2017, vol. 125, no. 3, pp. 176–182. DOI: 10.1055/s-0042-116071
  20. Gao X., Wang G., Wang A., Xu T., Tong W., Zhang Y. Comparison of lipid accumulation product with body mass index as an indicator of hypertension risk among Mongolians in China. Obes. Res. Clin. Pract., 2013, vol. 7, no. 4, pp. e308–314. DOI: 10.1016/j.orcp.2012.02.002
  21. Wang H., Chen Y., Sun G., Jia P., Qian H., Sun Y. Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population. Postgrad Med., 2018, vol. 130, no. 3, pp. 325–333. DOI: 10.1080/00325481.2018.1444901
  22. Zhong C., Xia W., Zhong X., Xu T., Li H., Zhang M. [et al.]. Lipid accumulation product and hypertension related to stroke: a 9.2-year prospective study among Mongolians in China. J. Atheroscler. Thromb., 2016, vol. 23, no. 7, pp. 830–838. DOI: 10.5551/jat.33514
  23. Zhang K., Li Q., Chen Y., Wang N., Lu Y. Visceral adiposity and renal function: an observational study from SPECT-China. Lipids Health Dis., 2017, vol. 16, pp. 205. DOI: 10.1186/s12944-017-0597-0
  24. Dai D., Chang Y., Chen Y., Chen S., Yu S., Guo X., Sun Y. Visceral adiposity index and lipid accumulation product index: two alternate body indices to identify chronic kidney disease among the rural population in northeast China. Int J. Environ. Res. Public. Health, 2016, vol. 13, no. 12, pp. 1231. DOI: 10.3390/ijerph13121231
  25. Kyrou I., Panagiotakos D.B., Kouli G.M., Georgousopoulou E., Chrysohoou C., Tsigos C. [et al.]. Lipid accumulation product in relation to 10-year cardiovascular disease incidence in Caucasian adults: The ATTICA study. Atherosclerosis, 2018, vol. 279, pp. 10–16. DOI: 10.1016/j.atherosclerosis.2018.10.015
  26. Ganguly S., Ray L., Kuruvila S., Nanda S.K., Ravichandran K. Lipid accumulation product index as visceral obesity indicator in psoriasis: a case-control study. Indian J. Dermatol, 2018, vol. 63, no. 2, pp. 136–140. DOI: 10.4103/ijd.IJD_315_16
  27. Glintborg D., Andersen M. Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. Curr. Opin. Obstet. Gynecol., 2017, vol. 29, no. 6, pp. 390–396. DOI: 10.1097/GCO.0000000000000410
  28. Cartolano F.C., Pappiani C., Freitas M.C.P., Figueiredo Neto A.M., Carioca A.A.F., Damasceno N.R.T. Is lipid accumulation product associated with an atherogenic lipoprotein profile in Brazilian subjects? Arq. Bras. Cardiol., 2018, vol. 110, no. 5, pp. 339–347. DOI: 10.5935/abc.20180054
  29. Tripolino C., Irace C., Carallo C., Scavelli F.B., Gnasso A. Body fat and blood rheology: Evaluation of the association between different adiposity indices and blood viscosity. Clin. Hemorheol Microcirc., 2017, vol. 65, no. 3, pp. 241–248. DOI: 10.3233/CH-16172
  30. Wakabayashi I. Associations of blood lipid-related indices with blood pressure and pulse pressure in middle-aged men. Metab. Syndr. Relat. Disord., 2015, vol. 13, no. 1, pp. 22–28. DOI: 10.1089/met.2014.0093
  31. Bhargava A. Dietary modifications and lipid accumulation product are associated with systolic and diastolic blood pressures in the women's health trial: Feasibility study in minority populations. Curr. Hypertens. Rep., 2018, vol. 20, no. 6, pp. 50. DOI: 10.1007/s11906-018-0846-2
  32. Wang H., Sun Y., Li Z., Guo X., Chen S., Ye N. [et al.]. Gender-specific contribution of cardiometabolic index and lipid accumulation product to left ventricular geometry change in general population of rural China. BMC Cardiovasc. Disord., 2018, vol. 18, no. 1, pp. 62. DOI: 10.1186/s12872-018-0798-0
  33. Chen Y., Chen Y., Wang N., Chen C., Nie X., Li Q. [et al.]. Thyroid stimulating hormone within the reference range is associated with visceral adiposity index and lipid accumulation product: A population-based study of SPECT-China. Horm Metab. Res., 2018, vol. 50, no. 1, pp. 29–36. DOI: 10.1055/s-0043-122235
  34. Wakabayashi I. Associations between heavy alcohol drinking and lipid-related indices in middle-aged men. Alcohol, 2013, vol. 47, no. 8, pp. 637–642. DOI: 10.1016/j.alcohol.2013.10.001
  35. Li X.X., Zhao Y., Huang L.X., Xu H.X., Liu X.Y., Yang J.J. [et al.]. Effects of smoking and alcohol consumption on lipid profile in male adults in northwest rural China. Public Health, 2018, vol. 157, pp. 7–13. DOI: 10.1016/j.puhe.2018.01.003
  36. Wakabayashi I. Smoking and lipid-related indices in patients with diabetes mellitus. Diabet Med., 2014, vol. 31, no. 7, pp. 868–878. DOI: 10.1111/dme.12430
  37. Green A.N., McGrath R., Martinez V., Taylor K., Paul D.R., Vella C.A. Associations of objectively measured seden-tary behavior, light activity, and markers of cardiometabolic health in young women. Eur. J. Appl. Physiol., 2014, vol. 114, no. 5, pp. 907–919. DOI: 10.1007/s00421-014-2822-0
  38. Mario F.M., Graff S.K., Spritzer P.M. Habitual physical activity is associated with improved anthropometric and andro-genic profile in PCOS: a cross-sectional study. J. Endocrinol. Invest., 2017, vol. 40, no. 4, pp. 377–384. DOI: 10.1007/s40618-016-0570-1
  39. Ji B.L., Li R., Zhang S.H., Gong L.L., Wang Z.H., Ren W., Li Q.F. The lipid accumulation product is highly related to serum alanine aminotransferase level in male adults. Nutr. Res., 2012, vol. 32, no. 8, pp. 581–587. DOI: 10.1016/j.nutres.2012.06.019
  40. De Oliveira A., Hermsdorff H.H., Cocate P.G., Santos E.C., Bressan J., Natali A.J. Accuracy of plasma interleukin-18 and adiponectin concentrations in predicting metabolic syndrome and cardiometabolic disease risk in middle-age Brazilian men. Appl. Physiol. Nutr. Metab., 2015, vol. 40, no. 10, pp. 1048–1055. DOI: 10.1139/apnm-2014-0487
  41. Ioachimescu A.G., Brennan D.M., Hoar B.M., Hoogwerf B.J. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity (Silver Spring), 2010, vol. 18, no. 9, pp. 1836–1844. DOI: 10.1038/oby.2009.453
  42. Bozorgmanesh M., Hadaegh F., Azizi F. Diabetes prediction, lipid accumulation product, and adiposity measures;
    6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis., 2010, vol. 9, pp. 45. DOI: 10.1186/1476-511X-9-45
  43. Omuse G., Maina D., Hoffman M., Mwangi J., Wambua C., Kagotho E. [et al.]. Metabolic syndrome and its predictors in an urban population in Kenya: A cross sectional study. BMC Endocr. Disord., 2017, vol. 17, no. 1, pp. 37. DOI: 10.1186/s12902-017-0188-0
  44. Oh J.Y., Sung Y.A., Lee H.J. The lipid accumulation product as a useful index for identifying abnormal glucose regu-lation in young Korean women. Diabet Med., 2013, vol. 30, no. 4, pp. 436–442. DOI: 10.1111/dme.12052
  45. Motamed N., Razmjou S., Hemmasi G., Maadi M., Zamani F. Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol. J. Endocrinol. Invest., 2016, vol. 39, no. 4, pp. 375–382. DOI: 10.1007/s40618-015-0369-5
  46. Abulmeaty M.M., Almajwal A.M., Almadani N.K., Aldosari M.S., Alnajim A.A., Ali S.B. [et al.]. Anthropometric and central obesity indices as predictors of long-term cardiometabolic risk among Saudi young and middle-aged men and women. Saudi. Med. J., 2017, vol. 38, no. 4, pp. 372–380. DOI: 10.15537/smj.2017.4.18758
  47. Wakabayashi I. Influence of age and gender on lipid accumulation product and its relation to diabetes mellitus in Jap-anese. Clin. Chim. Acta., 2014, vol. 431, pp. 221–226. DOI: 10.1016/j.cca.2014.02.002
  48. Chiang J.K., Koo M. Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over. BMC Cardiovasc. Disord., 2012, vol. 12, pp. 78. DOI: 10.1186/1471-2261-12-78
  49. Kahn H.S., Bullard K.M., Barker L.E., Imperatore G. Differences between adiposity indicators for predicting all-cause mortality in a representative sample of United States non-elderly adults. PLoS One, 2012, vol. 7, no. 11, pp. e50428. DOI: 10.1371/journal.pone.0050428
  50. Fu S., Luo L., Ye P., Xiao W. Multimarker analysis for new biomarkers in relation to central arterial stiffness and hemodynamics in a Chinese community-dwelling population. Angiology, 2015, vol. 66, no. 10, pp. 950–956. DOI: 10.1177/0003319715573910
  51. Joshi H., Shah K., Patel P., Prajapati J., Parmar M., Doshi D., Chaurushia S. Novel indexes for diagnosing metabolic syndrome in apparently healthy Gujarati Asian Indians: a cross-sectional study. QJM, 2016, vol. 109, no. 11, pp. 717–722. DOI: 10.1093/qjmed/hcw056
  52. Xiang S., Hua F., Chen L., Tang Y., Jiang X., Liu Z. Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes., 2013, vol. 121, no. 2, pp. 115–118. DOI: 10.1055/s-0032-1333261
  53. Taverna M.J., Martínez-Larrad M.T., Frechtel G.D., Serrano-Ríos M. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur. J. Endocrinol., 2011, vol. 164, no. 4, pp. 559–567. DOI: 10.1530/EJE-10-1039
  54. Hosseinpanah F., Barzin M., Erfani H., Serahati S., Ramezani Tehrani F., Azizi F. Lipid accumulation product and insulin resistance in Iranian PCOS prevalence study. Clin. Endocrinol. (Oxf), 2014, vol. 81, no. 1, pp. 52–57. DOI: 10.1177/2047487314558771
  55. Tian S., Xu Y., Han F. Higher predictability of the lipid accumulation product than commonly used anthropometric parameters partly due to its definition. Clin. Nutr., 2017, vol. 36, no. 3, pp. 909. DOI: 10.1016/j.clnu.2017.03.001
  56. Bozorgmanesh M., Hadaegh F., Azizi F. Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis., 2010, vol. 9, pp. 100. DOI: 10.1186/1476-511X-9-100
  57. Kavaric N., Klisic A., Ninic A. Are visceral adiposity index and lipid accumulation product reliable indices for metabolic disturbances in patients with type 2 diabetes mellitus? J. Clin. Lab. Anal., 2018, vol. 32, no. 3, pp. e22283. DOI: 10.1002/jcla.22283
  58. Li R., Li Q., Cui M., Ying Z., Li L., Zhong T. [et al.]. Visceral adiposity index, lipid accumulation product and intracranial atherosclerotic stenosis in middle-aged and elderly Chinese. Sci. Rep., 2017, vol. 7, no. 1, pp. 7951. DOI: 10.1038/s41598-017-07811-7
  59. Roriz A.K., Passos L.C., De Oliveira C.C., Eickemberg M., Moreira P.A., Sampaio L.R. Evaluation of the accuracy of anthropometric clinical indicators of visceral fat in adults and elderly. PLoS One, 2014, vol. 9, no. 7, pp. e103499. DOI: 10.1371/journal.pone.0103499
  60. Cheng Y.L., Wang Y.J., Lan K.H., Huo T.I., Huang Y.H., Su C.W. [et al.]. Fatty liver index and lipid accumulation product can predict metabolic syndrome in subjects without fatty liver disease. Gastroenterol Res. Pract., 2017, vol. 2017, pp. 9279836. DOI: 10.1155/2017/9279836
  61. Wang H., Chen Y., Guo X., Chang Y., Sun Y. Usefulness of cardiometabolic index for the estimation of ischemic stroke risk among general population in rural China. Postgrad Med., 2017, vol. 129, no. 8, pp. 834–841. DOI: 10.1080/00325481.2017.1375714
  62. Rashid N., Nigam A., Saxena P., Jain S.K., Wajid S. Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome. Inflamm Res., 2017, vol. 66, no. 7, pp. 621–636. DOI: 10.1007/s00011-017-1045-3
  63. Drapkina O.M., Shepel R.N., Shalnova S.A., Deev A.D., Balanova Y.A., Evstifeeva S.E. [et al.]. Anthropometric In-dices and Diabetes Mellitus Type 2 in Russian Population. Rational Pharmacotherapy in Cardiology, 2018, vol. 14, no. 5, pp. 725–732.
  64. Shalnova S.A., Deev A.D., Muromtseva G.A., Balanova J.A., Imaeva A.E., Kapustina A.V., Evstifeeva S.E. [et al.]. Relation of anthropometric indexes and coronary heart disease. Cardiovascular Therapy and Prevention, 2018, vol. 17, no. 3, pp. 11–16.
  65. Khripun I.A., Vorob'ev S.V., Kogan M.I. A new marker of metabolic disorders in men with type 2 diabetes. Med-itsinskii vestnik Yuga Rossii, 2016, no. 1, pp. 84–86 (in Russian).
  66. Kornoukhova L.A. Value of cardiovascular disorders’ predictors in patients with abdominal obesity, nonalcoholic fatty liver disease and various metabolic syndrome components. Meditsinskii alfavit, 2017, vol. 1, no. 6, pp. 51–56 (in Russian).
  67. Lwow F., Jedrzejuk D., Milewicz A., Szmigiero L. Lipid accumulation product (LAP) as a criterion for the identification of the healthy obesity phenotype in postmenopausal women. Exp. Gerontol., 2016, vol. 82, pp. 81–87. DOI: 10.1016/j.exger.2016.06.007
  68. Du T., Yu X., Zhang J., Sun X. Lipid accumulation product and visceral adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype. Acta. Diabetol., 2015, vol. 52, no. 5, pp. 855–863. DOI: 10.1007/s00592-015-0715-2
  69. Lin H., Zhang L., Zheng R., Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabol-ically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article. Medicine (Baltimore), 2017, vol. 96, no. 47, pp. e8838. DOI: 10.1097/MD.000000000000883
Received: 
21.01.2019
Accepted: 
03.06.2019
Published: 
30.06.2019

You are here

Home